137 related articles for article (PubMed ID: 11755457)
1. Assessing Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory: scoring and clinical implications.
Weiner MF; Tractenberg RE; Jin S; Gamst A; Thomas RG; Koss E; Thal LJ
J Psychiatr Res; 2002; 36(1):19-25. PubMed ID: 11755457
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the Cohen-Mansfield agitation inventory with the CERAD behavioral rating scale for dementia in community-dwelling persons with Alzheimer's disease.
Weiner MF; Koss E; Patterson M; Jin S; Teri L; Thomas R; Thal LJ; Whitehouse P
J Psychiatr Res; 1998; 32(6):347-51. PubMed ID: 9844950
[TBL] [Abstract][Full Text] [Related]
3. Assessing patterns of agitation in Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory. The Alzheimer's Disease Cooperative Study.
Koss E; Weiner M; Ernesto C; Cohen-Mansfield J; Ferris SH; Grundman M; Schafer K; Sano M; Thal LJ; Thomas R; Whitehouse PJ
Alzheimer Dis Assoc Disord; 1997; 11 Suppl 2():S45-50. PubMed ID: 9236952
[TBL] [Abstract][Full Text] [Related]
4. Estimating the prevalence of agitation in community-dwelling persons with Alzheimer's disease.
Tractenberg RE; Weiner MF; Thal LJ
J Neuropsychiatry Clin Neurosci; 2002; 14(1):11-8. PubMed ID: 11884649
[TBL] [Abstract][Full Text] [Related]
5. Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance.
Rabinowitz J; Davidson M; De Deyn PP; Katz I; Brodaty H; Cohen-Mansfield J
Am J Geriatr Psychiatry; 2005 Nov; 13(11):991-8. PubMed ID: 16286443
[TBL] [Abstract][Full Text] [Related]
6. Agitation-associated behavioral symptoms in mild cognitive impairment and Alzheimer's dementia.
Van der Mussele S; Le Bastard N; Saerens J; Somers N; Mariën P; Goeman J; De Deyn PP; Engelborghs S
Aging Ment Health; 2015; 19(3):247-57. PubMed ID: 24962058
[TBL] [Abstract][Full Text] [Related]
7. Frequency of behavioral symptoms characterizes agitation in Alzheimer's disease.
Tractenberg RE; Gamst A; Weiner MF; Koss E; Thomas RG; Teri L; Thal L
Int J Geriatr Psychiatry; 2001 Sep; 16(9):886-91. PubMed ID: 11571769
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal Course of Agitation and Aggression in Patients with Alzheimer's Disease in a Cohort Study: Methods, Baseline and Longitudinal Results of the A3C Study.
De Mauleon A; Delrieu J; Cantet C; Vellas B; Andrieu S; Rosenberg PB; Lyketsos CG; Soto Martin M
J Prev Alzheimers Dis; 2021; 8(2):199-209. PubMed ID: 33569568
[TBL] [Abstract][Full Text] [Related]
9. Behavioral syndromes in mild cognitive impairment and Alzheimer's disease.
Van der Mussele S; Mariën P; Saerens J; Somers N; Goeman J; De Deyn PP; Engelborghs S
J Alzheimers Dis; 2014; 38(2):319-29. PubMed ID: 23963290
[TBL] [Abstract][Full Text] [Related]
10. Psychometric evaluation of the Cohen-Mansfield Agitation Inventory in an acute general hospital setting.
Kupeli N; Vickerstaff V; White N; Lord K; Scott S; Jones L; Sampson EL
Int J Geriatr Psychiatry; 2018 Jan; 33(1):e158-e165. PubMed ID: 28560807
[TBL] [Abstract][Full Text] [Related]
11. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
[TBL] [Abstract][Full Text] [Related]
12. 24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer's Disease: Analyses from a Clinical Trial with Nabilone.
Ruthirakuhan M; Herrmann N; Andreazza AC; Verhoeff NPLG; Gallagher D; Black SE; Kiss A; Lanctôt KL
J Alzheimers Dis; 2019; 71(1):21-31. PubMed ID: 31322567
[TBL] [Abstract][Full Text] [Related]
13. [Cohen-Mansfield Agitation Inventory (CMAI)].
Homma A; Usui M
Nihon Rinsho; 2004 Apr; 62 Suppl 4():39-41. PubMed ID: 15174644
[No Abstract] [Full Text] [Related]
14. Agitated behaviours among the institutionalized elderly with dementia: validation of the Korean version of the Cohen-Mansfield Agitation Inventory.
Suh GH
Int J Geriatr Psychiatry; 2004 Apr; 19(4):378-85. PubMed ID: 15065232
[TBL] [Abstract][Full Text] [Related]
15. Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone.
Rabinowitz J; Katz IR; De Deyn PP; Brodaty H; Greenspan A; Davidson M
J Clin Psychiatry; 2004 Oct; 65(10):1329-34. PubMed ID: 15491235
[TBL] [Abstract][Full Text] [Related]
16. [Behavioral pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD): Spanish validation].
Boada M; Tárraga L; Modinos G; Diego S; Reisberg B
Neurologia; 2006; 21(1):19-25. PubMed ID: 16525922
[TBL] [Abstract][Full Text] [Related]
17. Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer's disease using risperidone.
Rabinowitz J; Katz I; De Deyn PP; Greenspan A; Brodaty H
Int Psychogeriatr; 2007 Apr; 19(2):227-40. PubMed ID: 16879763
[TBL] [Abstract][Full Text] [Related]
18. Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease.
Tao Y; Peters ME; Drye LT; Devanand DP; Mintzer JE; Pollock BG; Porsteinsson AP; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG; Munro CA
Am J Alzheimers Dis Other Demen; 2018 Nov; 33(7):450-457. PubMed ID: 29969907
[TBL] [Abstract][Full Text] [Related]
19. Behavioral outcomes in clinical trials for Alzheimer disease.
Ferris SH; Mackell JA
Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S10-5. PubMed ID: 9339267
[TBL] [Abstract][Full Text] [Related]
20. Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria.
De Mauleon A; Ismail Z; Rosenberg P; Miller D; Cantet C; O'Gorman C; Vellas B; Lyketsos C; Soto M
Alzheimers Dement; 2021 Oct; 17(10):1687-1697. PubMed ID: 34132461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
